SXTP
NASDAQ · Pharmaceuticals
60 Degrees Pharma Inc
$1.61
-0.22 (-12.02%)
Financial Highlights (FY 2026)
Revenue
14.67M
Net Income
-171,150,327
Gross Margin
43.5%
Profit Margin
-1,166.4%
Rev Growth
-52.5%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 43.5% | 43.5% | 46.3% | 46.3% |
| Operating Margin | -1,425.8% | -1,283.3% | 30.7% | 30.1% |
| Profit Margin | -1,166.4% | -1,108.1% | 23.1% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 14.67M | 30.89M | 862.6K | 990.0K |
| Gross Profit | 6.39M | 13.44M | 399.5K | 458.5K |
| Operating Income | -209,224,368 | -396,341,677 | 264.9K | 298.0K |
| Net Income | -171,150,327 | -324,216,573 | 198.9K | 215.4K |
| Gross Margin | 43.5% | 43.5% | 46.3% | 46.3% |
| Operating Margin | -1,425.8% | -1,283.3% | 30.7% | 30.1% |
| Profit Margin | -1,166.4% | -1,108.1% | 23.1% | 21.8% |
| Rev Growth | -52.5% | -52.5% | -6.7% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 88.7K | 88.7K | 1.77M | 1.68M |
| Total Equity | 2.30M | 2.30M | 3.39M | 2.90M |
| D/E Ratio | 0.04 | 0.04 | 0.52 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -206,784,719 | -413,482,389 | 334.7K | 417.4K |
| Free Cash Flow | — | — | 224.8K | 208.8K |